<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">THIABENDAZOLE</span><br/>(thye-a-ben'da-zole)<br/><span class="topboxtradename">Mintezol<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">anthelmintic</span><br/><b>Prototype: </b>Mebendazole<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg chewable tablets; 500 mg/5 mL suspension</p>
<h1><a name="action">Actions</a></h1>
<p>Structurally related to mebendazole. Precise mechanism of action is not clear, however, it has a wide spectrum of anthelmintic
         activity. Inhibits helminth-specific enzyme fumarate reductase.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Suppresses production of eggs or larvae by some parasites and may inhibit subsequent development of eggs or larvae passed
         in feces. Demonstrates antiinflammatory, antipyretic, and analgesic effects.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Enterobiasis (pinworm infestation), ascariasis (roundworm), strongyloidiasis (threadworm), cutaneous larva migrans (creeping
         eruption), and hookworm infestations caused by <i>Ancyclostoma duodenale</i> or <i>Necator americanus.</i> Used during invasive stage of trichinosis to relieve symptoms and for mixed helminthic infestations.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Safety during pregnancy (category C) or lactation is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Liver or kidney dysfunction; when vomiting can be dangerous, severe dehydration or malnutrition; anemia; children weighing
         
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Enterobiasis, Ascariasis, Strongyloidiasis, Hookworm</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 70 kg, 25 mg/kg b.i.d. times 2 d; &gt;<i>70 kg,</i> 1.5 g b.i.d. (max: 3 g/d) times 2 d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <i>1470 kg,</i> 25 mg/kg b.i.d. times 2 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give after meals. Chewable tablets must be chewed thoroughly before swallowing.</li>
<li>Shake suspension well before pouring.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Weariness, <span class="speceff-common">dizziness,</span> drowsiness, headache. <span class="typehead">CV:</span> Hypotension, bradycardia. <span class="typehead">GI:</span> <span class="speceff-common">Anorexia, nausea, vomiting,</span> epigastric distress, jaundice, cholestasis, parenchymal liver damage, diarrhea, perianal rash. <span class="typehead">Urogenital:</span> Malodor of urine, crystalluria, hematuria, nephrotoxicity, enuresis. <span class="typehead">Metabolic:</span> Transient rise in AST, transient leukopenia, hypersensitivity, hyperglycemia. <span class="typehead">Skin:</span> Pruritus. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> &gt;90% excreted in urine; 5% in feces. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Provide supportive treatment prior to therapy if patient is anemic, dehydrated, or malnourished.</li>
<li>Adverse effects generally occur 34 h after administration, are mild, and last for 28 h. Incidence tends to be
            related to dose and duration of treatment.
         </li>
<li>Discontinued immediately with S&amp;S of hypersensitivity: Fever, facial flush, chills, conjunctival infection, skin rashes, or
            erythema multiforme (including Stevens-Johnson syndrome), which can be fatal.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known. CNS adverse effects occur frequently.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>